{
  "trial_id": "NCT03936270",
  "overall_assessment": "likely_ineligible",
  "inclusion": [
    {
      "criterion": "Evidence of a personally signed and dated informed consent document indicating that the subject has been informed of all pertinent aspects of the study;",
      "label": "met"
    },
    {
      "criterion": "Subject is willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures;",
      "label": "met"
    },
    {
      "criterion": "18 years of age or older;",
      "label": "met"
    },
    {
      "criterion": "Histologically diagnosed endometrioid or high-grade serous ovarian cancer, estrogen (ER) and/or progesterone (PR) receptor positive (defined as > 10% by immunohistochemistry);",
      "label": "met"
    },
    {
      "criterion": "Patients must have completed 2 previous courses of chemotherapy: The penultimate regimen must be a platinum-based chemotherapy course prior to enrolment on the study;",
      "label": "not_met"
    },
    {
      "criterion": "Formalin fixed, paraffin embedded tumor sample from the primary tumor must be available for central testing;",
      "label": "met"
    },
    {
      "criterion": "Eastern Cooperative Oncology Group (ECOG) performance status \u2264 2;",
      "label": "met"
    },
    {
      "criterion": "Adequate bone marrow function at screening: Absolute Neutrophil Count (ANC) \u2265 1,500/mm\u00b3 (\u2265 1.5x10^9/L);",
      "label": "unknown"
    },
    {
      "criterion": "Adequate liver function at screening: Total serum bilirubin \u2264 1.5 x upper limit of normal (ULN);",
      "label": "met"
    },
    {
      "criterion": "Adequate renal function at screening: Serum creatinine \u2264 1.5 x ULN or estimated creatinine clearance \u2265 50mL/min;",
      "label": "unknown"
    },
    {
      "criterion": "Evidence of non-childbearing potential: Postmenopausal (defined as at least 1 year without any menses) prior to screening,",
      "label": "met"
    }
  ],
  "exclusion": [
    {
      "criterion": "Patients with a known hypersensitivity to Palbociclib or Letrozole or any of the excipients of the product;",
      "label": "unknown"
    },
    {
      "criterion": "Previous treatment with CDK inhibitors or endocrine therapy;",
      "label": "met"
    },
    {
      "criterion": "Patients receiving any chemotherapy, radiotherapy, within 3 weeks from the last dose prior to study entry;",
      "label": "unknown"
    }
  ],
  "notes": "The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam.",
  "_meta": {
    "topic_id": "25",
    "trial_id": "NCT03936270",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}